SIGA - 2000% pump

١٨ أغسطس

In March 2022, the stock of SIGA Technologies saw a significant increase due to growing concerns about the monkeypox outbreak. The primary driver of this growth was the World Health Organization (WHO) declaring the monkeypox outbreak a global health emergency. This attracted investors' attention to the company, as its main product, the antiviral drug Tecovirimat (TPOXX), was developed to treat smallpox and has proven effective against monkeypox.